February 9 Noon-Time Forum to Look at SGLT2 Inhibitors

February 3, 2022

The MMA’s next noon-time forum will examine sodium-glucose cotransporter-2 (SGLT2) inhibitors, a new 'triple play' for diabetes, cardiovascular and kidney diseases. The forum will take place February 9 from noon to 1 p.m.  

This forum will review the pharmacology of SGLT2 inhibitors and then discuss the role these drugs play in the management of type 2 diabetes. The evidence for improving cardiorenal outcomes will be presented and recommendations made for the use of these drugs in patients with cardiovascular or renal diseases. The session will conclude with a Q&A panel discussion. 

The forum will be moderated by Andrew Olson, MD, and include Anne Bantle, MD, Prabhjot S. Nijjar, MD, and Mark Rosenberg, MD. All faculty for this forum are with the University of Minnesota Medical School. 

Learning objectives for the forum include: 

  • Describe the pharmacology of SGLT2 inhibitors and the use of these drugs in the management of type 2 diabetes mellitus.  

  • Appraise the data supporting the cardiorenal protective effects of SGLT2 inhibitors.  

  • Utilize SGLT2 inhibitors in the management of patients with diabetes, cardiovascular or kidney diseases. 

To register, click here

The forum is free to members, $15 for non-members. This forum is being held in partnership with the University of Minnesota. 

Latest News

Allina Health Physicians Vote to Authorize Strike

July 9, 2026

More than 130 Allina Health hospital physicians represented by Doctors Council SEIU voted last week, by a 90% margin, to authorize a strike after nearly two years of bargaining.  

MMA Launches New Program to Strengthen Physician Well-being

July 9, 2026

The MMA is launching a new program, exclusive to members, to strengthen physician well-being, reduce professional isolation, build a culture of connection, and foster sustained peer connections over time.  

State Pursuing Medicaid Expansion to Treat Incarcerated People

July 9, 2026

Minnesota is pursuing a new initiative that, if approved by the federal government, will allow state Medicaid programs to cover certain behavioral health services and medical care for chronic health conditions for incarcerated people, for up to 90 days before release.